Cassava Sciences Reports 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Cassava Sciences, Inc. (SAVA)
Last cassava sciences, inc. earnings: 8/12 08:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
License agreement brings potential in a new therapeutic application for simufilam for seizures related to tuberous sclerosis complex (TSC) $128.6 Million in Cash and Cash Equivalents at December 31, 2024 AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, including Alzheimer's disease and tuberous sclerosis complex (TSC)-related seizures, today reported financial results for the year ended December 31, 2024 and provided a business update. “Cassava is preparing to report the topline results of the now-discontinued REFOCUS-ALZ, the second Phase 3 study of simufilam in Alzheimer's disease, in late first-quarter/early second-quarter 2025. We intend to evaluate the next steps for simufilam in Alzheimer's disease after reviewing the REFOCUS-ALZ results in conjunction with the results o
Show less
Read more
Impact Snapshot
Event Time:
SAVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAVA alerts
High impacting Cassava Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
SAVA
News
- Cassava Sciences rises 10% after market close on CEO stock buy [Seeking Alpha]Seeking Alpha
- Cassava Reports Q3 2025 Financials Results and Provides Business UpdateGlobeNewswire
- Cassava Sciences (NASDAQ:SAVA) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their RightsBusiness Wire
- Cassava Sciences Appoints Dawn C. Bir to the Board of DirectorsGlobeNewswire
SAVA
Earnings
- 3/3/25 - Beat
SAVA
Sec Filings
- 12/8/25 - Form EFFECT
- 12/5/25 - Form 424B2
- 12/3/25 - Form 8-K
- SAVA's page on the SEC website